CliffBio
small molecule

JENTADUETO XR

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Loss of exclusivityDecember 2037latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →View the full company profile on CliffBio

Drug detail

Brand nameJENTADUETO XR
Active ingredientLINAGLIPTIN; METFORMIN HYDROCHLORIDE
Strength5MG;1GM
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2016
Marketing statusRX

Listed patents

PatentExpiresType
12364700*PEDDecember 2037—
12364700June 2037use U-4224
9555001*PEDSeptember 2033—
9555001March 2033product
9155705*PEDNovember 2030—
9155705May 2030product
11911388April 2030use U-3854
9415016*PEDOctober 2029—
10022379*PEDOctober 2029—
10022379April 2029use U-2339
9415016April 2029product
9173859*PEDNovember 2027—
8673927*PEDNovember 2027—
8673927May 2027use U-1503
9173859May 2027product
8883805*PEDMay 2026—
8883805November 2025product

Regulatory exclusivity

CodeExpires
PEDDecember 2026
M-295June 2026

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JENTADUETO XR patent cliff — loss of exclusivity December 2037 | CliffBio